Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Increases By 34.8%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 186,200 shares, an increase of 34.8% from the October 15th total of 138,100 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily trading volume, of 135,200 shares, the short-interest ratio is currently 1.4 days.

ABVC BioPharma Price Performance

ABVC BioPharma stock opened at $0.55 on Friday. ABVC BioPharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.45. The firm has a market capitalization of $6.84 million, a PE ratio of -0.31 and a beta of 0.82. The company’s 50-day moving average is $0.62 and its 200-day moving average is $0.76.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.09) earnings per share for the quarter. ABVC BioPharma had a negative return on equity of 139.97% and a negative net margin of 8,363.97%. The business had revenue of $0.12 million for the quarter.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.